Clinical Trials Logo

Clinical Trial Summary

Blood contains red blood cells, white blood cells, and platelets, as well as a fluid portion termed plasma. We primarily study blood platelets, but sometimes we also analyze the blood of patients with red blood cell disorders (such as sickle cell disease), white blood cell disorders, and disorders of the blood clotting factors found in plasma. Blood platelets are small cell fragments that help people stop bleeding after blood vessels are damaged. Some individuals have abnormalities in their blood platelets that result in them not functioning properly. One such disorder is Glanzmann thrombasthenia. Most such patients have a bleeding disorder characterized by nosebleeds, gum bleeding, easy bruising (black and blue marks), heavy menstrual periods in women, and excessive bleeding after surgery or trauma. Our laboratory performs advanced tests of platelet function and platelet biochemistry. If we find evidence that a genetic disorder may be responsible, we analyze the genetic material (DNA and RNA) from the volunteer, and when possible, close family members to identify the precise defect.


Clinical Trial Description

After volunteers and family members agree to participate, they are seen in the Outpatient Research Center by the Principal Investigator or another physician. A detailed history is obtained, a physical examination is performed, and blood is obtained for further tests. Occasionally patients and family members are requested to return for additional tests. If an abnormality is identified with tests conducted in our research laboratory, we advise the volunteer to have the studies repeated in a laboratory certified to conduct tests on patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00230165
Study type Observational
Source Rockefeller University
Contact Recruitment Specialist
Phone 1-800-782-2737
Email rucares@rockefeller.edu
Status Recruiting
Phase
Start date September 2005
Completion date June 2024

See also
  Status Clinical Trial Phase
Terminated NCT01319851 - Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation N/A
Recruiting NCT02179359 - Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies N/A
Recruiting NCT04119908 - Videomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic Diseases N/A
Terminated NCT04548791 - Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders Phase 1/Phase 2
Not yet recruiting NCT06204042 - Multinational Glanzmann Study
Completed NCT04595617 - Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS) N/A
Completed NCT01917708 - Bone Marrow Transplant With Abatacept for Non-Malignant Diseases Phase 1
Active, not recruiting NCT03333486 - Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Phase 2
Recruiting NCT06211634 - A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia Phase 1/Phase 2
Completed NCT06234813 - Targeting TFPI With Concizumab to Improve Haemostasis in Glanzmann Thrombasthenia Patients: an in Vitro Study N/A
Completed NCT05315232 - The Experiences of People Who Live With Glanzmanns Thrombasthenia.